VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | Venetoclax & azacitidine for AML in 2020

Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, discusses the use of venetoclax and azacitidine for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Disclosures

Paresh Vyas, MRCP, FRCP, FRCPath, has been on advisory boards for Gilead and Agios.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter